01—Abstract
Summary
Summary of the 8-K filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported first-quarter 2024 results for the quarter ended March 29, 2024, as stated in Item 2.02 of this 8-K, which furnishes a press release (Exhibit 99.1) dated April 30, 2024.
Total revenues were $425.2 milliona, compared with $408.8 million a year earlier. Net product revenues were $378.5 million, up from $363.4 million, driven mainly by higher sales volume partially offset by lower average net selling price. GAAP net income was $37.3 million, or $0.12 per diluted share, versus $40.0 million, or $0.12, in the prior-year period.
Non-GAAP net income, which excludes stock-based compensation net of tax, was $52.0 millionb, or $0.17 per diluted share. The company recorded $32.8 million in restructuring expenses, primarily severance and employee-related costs, asset impairment and contract termination costs. Exelixis maintained its fiscal 2024 guidance, which excludes restructuring costs from the January 2024 restructuring plan: total revenues of $1.825 billion to $1.925 billion, net product revenues of $1.650 billion to $1.750 billion, R&D expenses of $925 million to $975 million, SG&A expenses of $425 million to $475 million, and an effective tax rate of 20% to 22%.
Cabozantinib franchise U.S. net product revenues were $378.5 millionc, and royalty revenues earned were $39.6 million. Management also cited Phase 3 CONTACT-02 (cabozantinib plus atezolizumab in mCRPC) PFS results and four-year CheckMate -9ER follow-up data, a ruling expected in spring 2024 in the second bench trial with MSN Pharmaceuticals, and a plan to repurchase up to an additional $450 million of stock before the end of 2024. The filing also describes pipeline priorities for 2024, including zanzalintinib pivotal trials, the XB002 ADC and XL309 USP1 inhibitor Phase 1 studies, and up to three Investigational New Drug filings this year, pending supportive preclinical data.
02—Key points
Key Highlights
- Total revenues of $425.2 million for Q1 2024, up from $408.8 million in Q1 2023.
- Net product revenues of $378.5 million, up from $363.4 million, driven by higher sales volume partially offset by lower average net selling price.
- GAAP diluted EPS of $0.12 (net income $37.3 million) versus $0.12 a year earlier; non-GAAP diluted EPS of $0.17 versus $0.16.
- Restructuring expenses of $32.8 million, primarily severance, asset impairment and contract termination costs.
- Fiscal 2024 guidance maintained: total revenues of $1.825 billion to $1.925 billion and net product revenues of $1.650 billion to $1.750 billion, excluding restructuring costs.
- Share repurchases: $190.7 million repurchased through March 31, 2024 at an average price of $22.08 per share, with up to $450 million more authorized for 2024.
- Litigation: ruling on the second bench trial with MSN Pharmaceuticals anticipated in spring 2024; EPO upheld European patent EP2593090 covering cabozantinib tablet formulations, subject to appeal.
03—Questions
Frequently Asked Questions
Did Exelixis meet or change its 2024 financial outlook?
Exelixis maintained its previously provided 2024 guidance. Total revenues are expected at $1.825 billion to $1.925 billion, net product revenues at $1.650 billion to $1.750 billion, R&D expenses at $925 million to $975 million, SG&A expenses at $425 million to $475 million, and an effective tax rate of 20% to 22%. The guidance excludes expenses related to the January 2024 restructuring plan.
Why did GAAP and non-GAAP earnings per share differ?
Non-GAAP net income excludes stock-based compensation expense, adjusted for the related income tax effect. In Q1 2024, stock-based compensation was $3.9 million in R&D and $15.2 million in SG&A, with a tax effect of $4.4 million. This brought GAAP diluted EPS of $0.12 to non-GAAP diluted EPS of $0.17. The company states that this exclusion is because stock-based compensation is non-cash and can vary significantly from period to period.
What drove the restructuring charge and what is the company's capital return plan?
The $32.8 million restructuring charge consists primarily of severance and employee-related costs, asset impairment and contract termination costs, tied to the restructuring announced in January 2024. Management says the restructuring is intended to enhance integrated research, development and commercial capabilities. Exelixis has repurchased $190.7 million of stock through March 31, 2024 and the Board authorized up to an additional $450 million to be repurchased before the end of 2024. Upon completion, the company expects to have returned $1 billion to shareholders over two years, together with the completed 2023 program.
What are the key upcoming catalysts mentioned in the filing?
The filing cites a ruling in the second bench trial with MSN Pharmaceuticals expected in the spring of 2024, the next overall survival analysis from the Phase 3 CONTACT-02 trial anticipated in 2024, and presentation of 10 cabozantinib and zanzalintinib abstracts at the 2024 ASCO Annual Meeting. The company also plans to provide updates on regulatory strategies for cabozantinib in neuroendocrine tumors and metastatic castration-resistant prostate cancer when appropriate, and expects up to three Investigational New Drug filings in 2024 pending supportive preclinical data.
04—Continue